ESPR (Esperion Therapeutics, Inc.) שיעור רווח גולמי

סמלים רשמיים של חברת Esperion Therapeutics Inc (ESPR)

Esperion Therapeutics (ESPR) is seeing gross profit margins expand following FDA and Medicare approvals that have triggered commercialization. The business relies on stable demand within cardiology, which remains independent of economic cycles. High profitability is driven by scalability, as development costs are offset by mass sales. The current value is maintained at 68.40, confirming the efficiency of direct cost management.

רווחיות גולמית: esperion.com (ESPR) עבור 04.07.2022 - 25.07.2026

פילוחים אנליטיים ודוחות נתונים של חברת Esperion Therapeutics Inc (ESPR)

- שער מניה ותחזית מחירי מומחים:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית:ESPR Esperion Therapeutics Inc
מוצר המיוצר על ידי Esperion Therapeutics, Inc.

Gross margin measures primary production efficiency by determining the portion of revenue remaining after deducting direct product creation costs. An analysis of the gross profit margin allows for an assessment of how royalties from global partners of Esperion Therapeutics (ESPR) impact overall profitability, where an increase in this metric confirms the high added value of innovative cardiology drugs alongside the optimization of distribution costs.